Enhancement of Human Melanoma Antigen Expression by IFN-β
Authors:
- 15 August 2007
- journal article
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 179 (4) , 2134-2142
Abstract
Although many immunotherapeutic investigations have focused on improving the effector limb of the antitumor response, few studies have addressed preventing the loss of tumor-associated Ag (TAA) expression, associated with immune escape by tumors. We found that TAA loss from human melanomas usually results from reversible gene down-regulation, rather than gene deletion or mutation. Previously, we showed that inhibitors of MAPK-signaling pathways up-regulate TAA expression in melanoma cell lines. We have now identified IFN-β as an additional stimulus to TAA expression, including Melan-A/MART-1, gp100, and MAGE-A1. IFN-β (but neither IFN-α nor IFN-γ) augmented both protein and mRNA expression of melanocytic TAA in 15 melanoma lines (irrespective of initial Ag-expression levels). Treatment of low Ag melanoma lines with IFN-β increased expression of melanocyte-lineage Ags, inducing susceptibility to lysis by specific CTLs. Treatment with IFN-β also enhances expression of class I HLA molecules, thereby inducing both nominal TAA and the presenting HLA molecule. Data from fluorescent cellular reporter systems demonstrated that IFN-β triggers promoter activation, resulting in augmentation of Ag expression. In addition to enhancing TAA expression in melanomas, IFN-β also stimulated expression of the melanocytic Ag gp100 in cells of other neural crest-derived tumor lines (gliomas) and certain unrelated tumors. Because IFN-β is already approved for human clinical use in other contexts, it may prove useful as a cotreatment for augmenting tumor Ag expression during immunotherapy.Keywords
This publication has 49 references indexed in Scilit:
- A critical function for type I interferons in cancer immunoeditingNature Immunology, 2005
- Development of interferon-β as a therapy for multiple sclerosisExpert Opinion on Emerging Drugs, 2004
- Current developments of immunotherapy in the clinicCurrent Opinion in Immunology, 2004
- Enhancing CTL responses to melanoma cell vaccines in vivo: synergistic increases obtained using IFNγ primed and IFNβ treated B7‐1+ B16‐F10 melanoma cellsImmunology & Cell Biology, 2003
- Adoptive transfer of an anti‐MART‐127–35‐specific CD8+ T cell clone leads to immunoselection of human melanoma antigen‐loss variants in SCID miceEuropean Journal of Immunology, 2003
- Human and Mouse IFN-β Gene Therapy Exhibits Different Anti-tumor Mechanisms in Mouse ModelsMolecular Therapy, 2001
- Differences in Activity between α and β Type I Interferons Explored by Mutational AnalysisJournal of Biological Chemistry, 1998
- Interferons up-regulate with different potency HLA class I antigen expression in M14 human melanoma cell line. Possible interaction with glucocorticoid hormonesCancer Immunology, Immunotherapy, 1995
- Modulation of the antigenic phenotype of human breast carcinoma cells by modifiers of protein kinase C activity and recombinant human interferonsCancer Immunology, Immunotherapy, 1992
- Modulation of the antigenic phenotype of early‐passage human melanoma cells derived from multiple autologous metastases by recombinant human leukocyte, fibroblast and immune interferonInternational Journal of Cancer, 1990